The Hsp90/Cdc37 (heat shock protein 90; cell division cycle 37) interaction is a promising target for anticancer
candidate drug development. The purpose of this research is to establish a screening method for anti-cancer candidate
compounds based on the Hsp90/Cdc37 interaction model in vitro by Split Renilla luciferase protein fragment-assisted
complementation bioluminescence technology. The parameters influencing the protein binding in this model were optimized,
including protein concentration, reaction time, and substrate concentration. The optimal condition was as follows:
protein concentration 2µM, the ratio of Hsp90 and Cdc37 1:1, reaction time 10 min, and the GLO® substrate (Promega,
Madison, WI, USA) dilution 1:100. The screening model was further validated by some known compounds blocking the
Hsp90/Cdc37 interactions. It was proved that this method is rapid and sensitive and could be used for screening of antipancreatic
cancer candidate compounds.
Keywords: Anti-cancer, Cdc37, a screening method, Hsp90, Hsp90/Cdc37 interaction, protein interaction model in vitro, SRLPFAC.
Rights & PermissionsPrintExport